120P - Survival outcomes of metastatic breast cancer who have been treated with bevacizumab and eribulin in the real world. - BEV + PTX followed by eribul...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Metastatic
Presenter Koshi Matsui
Citation Annals of Oncology (2016) 27 (suppl_9): ix35-ix41. 10.1093/annonc/mdw577
Authors K. Matsui1, M. Earashi2, T. Nagata3, A. Yoshikawa4, W. Fukushima5, Z. Nozaki6, Y. Tanada6, K. Oyama7, K. Shimada8, K. Kiyohara9, T. Shimizu10, K. Iwata11, T. Yoshida12, T. Ii13, K. Maeda1
  • 1Surgery, Toyama Prefectural Central Hospital, 9308550 - Toyama/JP
  • 2Surgery, Yatsuo General Hospital, 9392376 - Toyama/JP
  • 3Surgery And Science, Toyama University Hospital, 9300194 - Toyama/JP
  • 4Surgery, Toyama City Hospital, 9398511 - Toyama/JP
  • 5Surgery, Takaoka City Hospital, 9338550 - Takaoka/JP
  • 6Surgery, Toyama Red Cross Hospital, 9300859 - Toyama/JP
  • 7Surgery, Kouseiren Takaoka Hospital, 9338555 - Takaoka/JP
  • 8Surgery, Imizu Municipal Hospital, 9340053 - Imizu/JP
  • 9Surgery, Tonami Genaral Hospital, 9391395 - Tonami/JP
  • 10Surgery, Saiseikai Toyama Hospital, 9318533 - Toyama/JP
  • 11Surgery, Kurobe City Hospital, 9388502 - Kurobe/JP
  • 12Surgery, Saiseikai Takaoka Hospital, 9308550 - Takaoka/JP
  • 13Surgery, Kouseiren Namerikawa Hospital, 9368585 - Namerikawa/JP



bevacizumab and eribulin represent novel agents for the treatment of HER2-negative metastatic breast cancer (MBC). However, there are difficult situations in making a clinical decision of when to choose which treatment option. Purpose A purpose of this study is to clarify a prognostic difference by the drug sequence in the real world. We used the database of Toyama Breast Cancer Research Group (TBCRG: multicenter study group) to evaluate whether sequential order of treatment affects survival benefit in patients who have been treated with both bevacizumab + paclitaxel (BEV+PTX) and eribulin.


All patients who started BEV + PTX and eribulin treatment for MBC from Aug-2011 to Jun-2016 were selected in the database of TBCRG. Among 264 patients recorded in the TBCRG database, 180 patients had HER2-negative MBC. Of these, 55 patients were treated with both BEV + PTX and eribulin sequentially regardless of treatment line. To evaluate the influence of sequential order, we compared the efficacy of eribulin followed by BEV + PTX (arm E-B) to treatment with the reverse sequence (arm B-E).


28 patients were treated with E-B and 27 patients with the B-E sequence. The median progression free survival (PFS) was 9.6 and 14.1 months in arm E-B and arm B-E, respectively (p = 0.04). The median PFS with eribulin treatment was 3.7 and 4.1 months, respectively (p = 0.57). On the other hand, there was a significant difference in the median PFS with BEV + PTX treatment; 6.2 and 11.5 months, respectively (p = 0.006). The respective median OS time was 17.7 and 26.1 months (p = 0.11).


These results suggest that when patients with HER2-negative MBC are treated with both BEV + PTX and eribulin, patients with prior BEV + PTX treatment is more likely to benefit than patients who are treated with prior eribulin treatment.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.